Indivior PLC (NASDAQ:INDV) Sees Significant Drop in Short Interest

Indivior PLC (NASDAQ:INDV) saw a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 1,220,000 shares, a drop of 14.1% from the January 31st total of 1,420,000 shares. Currently, 1.1% of the shares of the stock are sold short. Based on an average daily volume of 1,230,000 shares, the days-to-cover ratio is currently 1.0 days.

Hedge Funds Weigh In On Indivior

Several large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in shares of Indivior during the fourth quarter valued at about $36,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Indivior in the 4th quarter worth about $56,000. Lazard Asset Management LLC purchased a new stake in shares of Indivior during the fourth quarter worth $57,000. Stifel Financial Corp bought a new stake in Indivior during the 3rd quarter worth approximately $100,000. Finally, Melqart Asset Management UK Ltd purchased a new stake in shares of Indivior in the third quarter worth $132,000. 60.33% of the stock is currently owned by institutional investors.

Indivior Trading Up 5.8 %

Shares of NASDAQ INDV opened at $10.10 on Wednesday. Indivior has a 1-year low of $7.33 and a 1-year high of $22.53. The company has a fifty day moving average price of $11.06 and a 200 day moving average price of $10.63. The firm has a market cap of $1.39 billion, a PE ratio of -28.86 and a beta of 0.73.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.32. The business had revenue of $298.00 million for the quarter, compared to analysts’ expectations of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. Equities research analysts forecast that Indivior will post 1.22 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on INDV shares. RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw assumed coverage on Indivior in a report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 target price on the stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.